Companies Dominating the Regenerative Xenograft Landscape
- ANTICANCER, INC.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- LLC
- eGenesis
- Iconic Therapeutics
- Revivicor, Inc.
- Viscus Biologics
- BioMarker Strategies LLC
- Batu Biologics
- AlloSource
- ANDROBIOSYS, INC.
Browse Key Market Insights with Data Illustration:
In the News
- eGenesis, a biotechnology firm growing human-compatible (HuCo) organs for the therapy of organ failure, declared the publication in the journal Nature of Permanent Survival Information from a proof-of-theory study assessing engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This information set will support the modification of the organization’s lead candidate for kidney transplant, EGEN-2784, toward clinical growth.
- eGenesis, Inc. and Eledon Pharmaceuticals, Inc. declared that they have come into a cooperative research deal under which eGenesis will acquire entrance to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ continuous preclinical research and development studies of human-agreeable organs and cells for the therapy of organ failure. The cooperation has the power to span numerous eGenesis programs involving kidney, heart, and islet cell transplants.
